🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Improving Quality of Life for Patients With Breast Cancer Invading the Chest Wall: A Prospective Registry For Patients Undergoing Full Thickness Chest Wall Resection

Recruitingn/aAges 18 Years - anyAllUniversity Health Network, Toronto
NCT03265379 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Although chest wall recurrence of breast cancer is uncommon, it represents a difficult clinical scenario. The role of full thickness chest wall resection (FTCWR) for breast cancer recurrence in the chest wall is controversial and is complicated by the fact that no prospective evidence exists evaluating the utility of FTCWR in prolonging survival or improving health related quality of life (HRQOL) and thus, there is a lack of evidence to guide treatment decisions. Gathering HRQOL, local-regional recurrence (LRR) and survival data in a prospective fashion is thus critical in this population. Therefore, we designed a prospective trial to evaluate the outcomes for FTCWR in terms of LRC and HRQOL, and short-term morbidity and mortality, with secondary focus on potential long-term overall survival benefit.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. \>18 years of age 2. Breast cancer with invasion of the chest wall (ribs, para-costal soft tissue, intercostal muscle or soft-tissue) that is: 1. Radiologically proven on cross-sectional imaging 2. Histologically proven 3. Medically fit for surgery 4. \>1 year disease-free interval (between initial treatment and recurrence) for patients with local recurrence Exclusion Criteria: 1. Medically inoperable due to co-morbidity or other contraindication to surgery 2. Technically unresectable disease 3. Ineligible for chemotherapy 4. ECOG performance status \>2 5. Patient refusal
💊

What it tests

  • FACT-B and Brief Pain Inventory
📍

Where

1 site
University Health Network (Toronto General Hospital and Princess Margaret Cancer Centre)
Toronto, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy